학술논문

Clinical evaluation of sparfloxacin for the treatment of paranasal sinusitis / 副鼻腔炎に対するSparfloxacinの臨床的検討
Document Type
Journal Article
Author
Source
耳鼻と臨床 / jibi to rinsho. 1991, 37(5):961
Subject
SPFX
Sparfloxacin
sinusitis
Language
Japanese
ISSN
0447-7227
2185-1034
Abstract
Sparfloxacin (SPFX) was evaluated for its efficacy, safety and usefulness in the treatment of paranasal sinusitis. SPFX was administered in single or divided doses of 200mg to 300mg daily.The efficacy rate judged by the doctor in charge was 87.0% in cases of acute paranasal sinusitis, 74.1% in cases of acute exacerbated paranasal sinusitis, 66.7% in cases of chronic paranasal sinusitis and 80.5% in all cases. The efficacy rate judged by the committee was 87.0% in acute cases, 66.7% in acute exacerbated cases, 66.7% in chronic cases and 78.0% in all cases.The bacteriological eradication rate was 93.2% in gram-positive bacteria, 100% in gram-negative bacteria, 80.0% in anaerobic bacteria and 94.4% in all bacteria.Side effects were observed in 5 cases and abnormal clinical laboratory findings occurred in 3 cases. The rate of usefulness judged by the doctor in charge was 85.1% in acute cases, 63.0% in acute exacerbated cases, 66.7% in chronic cases and 75.9% in all cases.These results indicate that SPFX is useful in the treatment of paranasal sinusitis.